A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants

This Phase 1/2 study is testing a new investigational drug called REGN7041 — given by eye injection or IV — for adults with active non-infectious uveitis, an inflammatory condition inside the eye that can cause vision loss if untreated. This is the first time REGN7041 is being tested in humans, and researchers want to understand its safety, how much drug reaches the eye and bloodstream, and whether the body makes antibodies against it. Adults with a confirmed diagnosis of non-infectious uveitis affecting the posterior segment (back of the eye), with active inflammation and reduced visual acuity at baseline, are eligible — those with infectious uveitis, very low eye pressure, or very poor vision (20/250 or worse) are excluded. Participation involves receiving study drug injections and attending regular clinic visits for eye exams, blood draws, and safety monitoring. This summary was prepared with AI assistance to help patients understand the study in plain language.